Christiane Verhaegen

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.

Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.